Sex Differences in Lopinavir and Ritonavir Pharmacokinetics Among HIV-Infected Women and Men.

Autor: Umeh, Obi C., Currier, Judith S., Park, Jeong-Gun, Cramer, Yoninah, Hermes, Ashwaq E., Fletcher, Courtney V.
Předmět:
Zdroj: Journal of Clinical Pharmacology; Dec2011, Vol. 51 Issue 12, p1665-1673, 9p
Abstrakt: The authors compared the pharmacokinetics of lopinavir (LPV) and ritonavir (RTV) between women and men. This 2-step, multicenter, pharmacokinetic study enrolled human immunodeficiency virus (HIV)–infected adults on lopinavir/ritonavir (LPV/r) capsules (400/100 mg bid) plus 1 or more nucleoside reverse transcriptase inhibitors. All participants underwent 12-hour pharmacokinetic sampling. The pharmacokinetic sampling was repeated in participants receiving the LPV/r tablet formulation. Step 1 enrolled 37 women and 40 men; step 2 included 42 participants from step 1 plus 35 new participants (39 women and 38 men). LPV pharmacokinetics in women and men were not significantly different with either formulation. Women had significantly higher median RTV AUC0-12 h with both the soft-gel capsule (SGC) and tablet formulations (SGC: 5395 vs 4119 ng·h/mL, P = .026; tablet: 5310 vs 3941 ng·h/mL, P = .012), higher median Cmax (SGC: 802 vs 635 ng/mL, P = .032; tablet: 773 vs 570 ng/mL, P = .006), and lower median CL/F (SGC: 18.54 vs 24.31 L/h, P = .026; tablet: 18.83 vs 25.37 L/h, P = .012). RTV CL/F was slower in women after weight adjustment with both formulations. The pharmacokinetics of LPV in the SGC and tablet formulations are comparable in HIV-infected patients. Women had higher RTV AUC0-12 h and lower CL/F with both formulations. The mechanism of the sex difference in RTV CL/F warrants elucidation. [ABSTRACT FROM PUBLISHER]
Databáze: Complementary Index
Externí odkaz: